Compare Dow Inc (DOW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dow Inc trades at $30.64 (market cap $22.58B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Dow Inc is far larger — about 287.5× Inovio Pharmaceuticals Inc's market cap, and Dow Inc pays a 4.48% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DOW | INO | |
|---|---|---|
Market Cap | $22.58B | $78.55M |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $2.87 |
52-Week Low | $20.65 | $0.66 |
Enterprise Value | $38.27B | $49.56M |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.78, up 0.65% today, with a bullish technical signal and positive earnings beats in recent quarters. However, the company reported a net loss of $2.62 billion in 2025, with declining revenue and negative profit margins. Analyst consensus is a 'Hold' with a $35.11 price target, suggesting modest upside potential from current levels.
The outlook is mixed; earnings improvements and dividend payments provide support, but persistent losses and high debt pose risks. Investment opportunity hinges on a turnaround in profitability, while key risks include competitive pressures and macroeconomic headwinds affecting the chemicals sector.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
